{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:19:34Z","timestamp":1759342774869},"reference-count":21,"publisher":"Japan Society for Clinical Immunology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2177\/jsci.39.64","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T22:07:14Z","timestamp":1463177234000},"page":"64-71","source":"Crossref","is-referenced-by-count":32,"title":["Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy"],"prefix":"10.2177","volume":"39","author":[{"given":"Sumie","family":"HIRAMATSU","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"OHMURA","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"TSUJI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"KAWABATA","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"KITANO","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"SOGABE","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"HASHIMOTO","sequence":"additional","affiliation":[{"name":"Department of the Control for Rheumatic Diseases, Kyoto University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"MURAKAMI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"IMURA","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoichiro","family":"YUKAWA","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"YOSHIFUJI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"FUJII","sequence":"additional","affiliation":[{"name":"Department of the Control for Rheumatic Diseases, Kyoto University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"TAKAORI-KONDO","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneyo","family":"MIMORI","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kawabata, H., et al.: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). <i>Journal of clinical and experimental hematopathology<\/i>. <b>53<\/b>: 57-61, 2013.","DOI":"10.3960\/jslrt.53.57"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Inoue, M., et al.: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. <i>Journal of clinical and experimental hematopathology<\/i>. <b>53<\/b>: 95-99, 2013.","DOI":"10.3960\/jslrt.53.95"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Iwaki, N., et al.: Atypical hyaline vascular-type castleman&apos;s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. <i>Journal of clinical and experimental hematopathology<\/i>. <b>53<\/b>: 87-93, 2013.","DOI":"10.3960\/jslrt.53.87"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kawabata, H., et al.: Successful treatment of a patient with multicentric Castleman&apos;s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. <i>Internal medicine<\/i> (Tokyo, Japan), <b>52<\/b>: 1503-1507, 2013.","DOI":"10.2169\/internalmedicine.52.9482"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Masaki, Y., et al.: Japanese variant of multicentric castleman&apos;s disease associated with serositis and thrombocytopenia \u2013 a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? <i>Journal of clinical and experimental hematopathology<\/i>. <b>53<\/b>: 79-85, 2013.","DOI":"10.3960\/jslrt.53.79"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Takai, K., et al.: Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. <i>Journal of clinical and experimental hematopathology<\/i>. <b>53<\/b>: 63-68, 2013.","DOI":"10.3960\/jslrt.53.63"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Awano, N., et al.: Mixed-type multicentric Castleman&apos;s disease developing during a 17-year follow-up of sarcoidosis. <i>Internal medicine<\/i> (Tokyo, Japan). <b>51<\/b>: 3061-3066, 2012.","DOI":"10.2169\/internalmedicine.51.8120"},{"key":"8","unstructured":"8) Ozawa, T., et al.: [Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman&apos;s disease]. [Rinsho ketsueki] <i>The Japanese journal of clinical hematology<\/i>. <b>55<\/b>: 350-355, 2014."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tedesco, S., et al.: Successful treatment of a Caucasian case of multifocal Castleman&apos;s disease with TAFRO syndrome with a pathophysiology targeted therapy \u2013 a case report. <i>Experimental hematology &amp; oncology<\/i>. <b>4<\/b>: 3, 2015.","DOI":"10.1186\/2162-3619-4-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kubokawa, I., et al.: The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman&apos;s disease. <i>BMC pediatrics<\/i>. <b>14<\/b>: 139, 2014.","DOI":"10.1186\/1471-2431-14-139"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Jain, P., et al.: Durable remission with rituximab in a patient with an unusual variant of Castleman&apos;s disease with myelofibrosis-TAFRO syndrome. <i>American journal of hematology<\/i>. <b>90<\/b>: 1091-1092, 2015.","DOI":"10.1002\/ajh.24015"},{"key":"12","unstructured":"12) \u77f3\u4e95\u3000\u771f\uff0c\u4ed6\uff1a\u75c5\u7406\u7d44\u7e54\u50cf\u304c\u8a3a\u65ad\u306e\u5951\u6a5f\u3068\u306a\u3063\u305fTAFRO\u75c7\u5019\u7fa4\u306e1\u4f8b\uff0e\u8a3a\u65ad\u75c5\u7406\uff0e<b>31<\/b>: 354-360, 2014."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Konishi, Y., et al.: Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman&apos;s Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2. <i>The Tohoku journal of experimental medicine<\/i>. <b>236<\/b>: 289-295, 2015.","DOI":"10.1620\/tjem.236.289"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tatekawa, S., et al.: Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. <i>Clinical case reports<\/i>. <b>3<\/b>: 472-478, 2015.","DOI":"10.1002\/ccr3.284"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kawashima, M., et al.: TAFRO syndrome: 2 cases and review of the literature. <i>Mod Rheumatol<\/i>. 1-5, 2015.","DOI":"10.3109\/14397595.2015.1059982"},{"key":"16","unstructured":"16) Soumerai, J.D., et al.: Diagnosis and management of Castleman disease. <i>Cancer control: journal of the Moffitt Cancer Center<\/i>. <b>21<\/b>: 266-278, 2014."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kanda, J., et al.: Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. <i>International journal of hematology<\/i>. <b>85<\/b>: 207-211, 2007.","DOI":"10.1532\/IJH97.06186"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Man, L., Goudar, R.K.: Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman&apos;s disease. <i>European journal of haematology<\/i>. <b>91<\/b>: 273-276, 2013.","DOI":"10.1111\/ejh.12161"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hirota, H., et al.: Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. <i>Heart and vessels<\/i>. <b>19<\/b>: 237-241, 2004.","DOI":"10.1007\/s00380-004-0770-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ancey, C., et al.: Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. <i>Cardiovascular research<\/i>. <b>59<\/b>: 78-85, 2003.","DOI":"10.1016\/S0008-6363(03)00346-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hirota, H., et al.: Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. <i>Proceedings of the National Academy of Sciences of the United States of America<\/i>. <b>92<\/b>: 4862-4866, 1995.","DOI":"10.1073\/pnas.92.11.4862"}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_64\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:39:17Z","timestamp":1498311557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_64\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.39.64","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}